Risk of venous thromboembolism during treatment with antipsychotic agents

Psychiatry and Clinical Neurosciences

Volumn 66, Issue 7, 2012, Pages 541-552

  Masopust, Jiří ^a   Malý, Radovan ^b   Vališ, Martin ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

Author keywords

antipsychotics; pulmonary embolism; risk factors; thrombosis; venous thromboembolism

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE; CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PHENOTHIAZINE; PROCHLORPERAZINE; QUETIAPINE; RISPERIDONE; SERTINDOLE; ZIPRASIDONE; ZOTEPINE; ZUCLOPENTHIXOL;

AGRANULOCYTOSIS; BLOOD CLOTTING; CARDIOMYOPATHY; CARDIOVASCULAR RISK; DROWSINESS; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG SAFETY; EMBOLISM PREVENTION; EPILEPSY; HUMAN; LOW DRUG DOSE; LUNG EMBOLISM; MENTAL PATIENT; MYOCARDITIS; NAUSEA; PATHOGENESIS; PATIENT MOBILITY; PHARMACOEPIDEMIOLOGY; PHYSICAL ACTIVITY; PRACTICE GUIDELINE; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; RECEPTOR AFFINITY; REVIEW; SIDE EFFECT; THROMBOSIS PREVENTION; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM; VERTIGO; VOMITING;

ANTIPSYCHOTIC AGENTS; HUMANS; PSYCHOTIC DISORDERS; RISK; VENOUS THROMBOEMBOLISM;

EID: 84872964929     PISSN: 13231316     EISSN: 14401819     Source Type: Journal    
DOI: 10.1111/pcn.12001     Document Type: Review

References (79)

1. De Hert M, Correll C, Bobes J, et al. Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry 2011; 10: 52-77.
2. De Hert M, Cohen D, Bobes J, et al. Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level. World Psychiatry 2011; 10: 138-151.
3. Kozumplik O, Uzun S, Jakovljevic M,. Metabolic syndrome in patients with psychotic disorders: Diagnostic issues, comorbidity and side effects of antipsychotics. Psychiatr. Danub. 2010; 22: 69-74.
4. Hägg S, Jönsson A, Spigset O,. Risk of venous thromboembolism due to antipsychotic drug therapy. Expert Opin. Drug Saf. 2009; 8: 537-547.
5. Cohen A, Agnelli G, Anderson F, et al. Venous thromboembolism (VTE) in Europe-The number of VTE events and associated morbidity and mortality. Thromb. Haemost. 2007; 98: 756-764.
6. Lijfering WM, Rosendaal FR, Cannegieter SC,. Risk factors for venous thrombosis-current understanding from an epidemiological point of view. Br. J. Haematol. 2010; 149: 824-833.
7. Grahmann H, Suchenwirth R,. Thrombose hazard in chlorpromazine and reserpine therapy of endogenous psychosis. Nervenarzt 1959; 30: 224-225.
8. Meier-Ewert K, Baumgart H, Friedeberg P,. Tromboembolische Komplikationen bei neuro- und thymoleptischer Behandlung. Dtsch. Med. Wochenschr. 1967; 92: 2174-2178.
9. Thomassen R, Vanderbroucke J, Rosendaal F,. Antipsychotics medication and venous thrombosis. Br. J. Psychiatry 2001; 179: 63-66.
10. Zornberg G, Jick H,. Antipsychotic drug use and risk of first-time idiopathic venous thromboembolism: A case control study. Lancet 2000; 356: 1219-1223.
11. Walker A, Lanza L, Arellano F, Rothman K,. Mortality in current and former users of clozapine. Epidemiology 1997; 8: 671-677.
12. Hägg S, Spigset O, Söderström T,. Association of venous thromboembolism and clozapine. Lancet 2000; 355: 1155-1156.
13. Parkin, L, Skety, DC, Herbison, GP, Skety, DC,. Psychotropic drugs and fatal pulmonary embolism. Pharmacoepidemiol. Drug Saf. 2004; 13: 659-650.
14. Liperoti R, Pedone C, Lapane K, Mor V, Bernabei R, Gambassi G,. Venous thromboembolism among elderly patients treated with atypical and conventional antipsychotic agents. Arch. Intern. Med. 2005; 165: 2677-2682.
15. Ray J, Mamdani M, Yeo E,. Antipsychotic and antidepressant drug use in the elderly and risk of venous thromboembolism. Thromb. Haemost. 2002; 88: 205-209.
16. Hamanaka S, Kamijo Y, Nagai T, et al. Massive pulmonary thromboembolism demonstrated at necropsy in Japanese psychiatric patients treated with neuroleptics including atypical antipsychotics. Circ. J. 2004; 68: 850-852.
17. Masopust J, Malý R, Urban A, Hosák L, Cermá ková E,. Antipsychotic drugs as a risk factor for venous thromboembolism. Int. J. Psych. Clin. Practice 2007; 11: 246-249.
18. Lacut K, Le Gal G, Couturaud F, et al. Association between antipsychotic drugs, antidepressant drugs and venous thrmoboembolism: results from the EDITH case-control study. Fundam. Clin. Pharmacol. 2007; 21: 643-650.
19. Hägg S, Bate A, Stahl M, Spigset O,. Associations between venous thromboembolism and antipsychotics-A study of the WHO database of adverse drug reactions. Drug Saf. 2008; 31: 685-694.
20. Jönsson AK, Brudin L, Ahlner J, Hedenmalm K, Ericsson A, Hägg S,. Antipsychotics associated with pulmonary embolism in a Swedish medicolegal autopsy series. Int. Clin. Psychopharmacol. 2008; 23: 263-268.
21. Jönsson AK, Horváth-Puhõ E, Hägg S, Pedersen L, Sorensen HT,. Antipsychotics and risk of venous thromboembolism: A population-based case-control study. Clin. Epidemiol. 2009; 1: 19-26.
22. Kleijer B, Heerdink E, van MR,. Antipsychotics and venous thrombosis. Dutch experience differs. BMJ 2010; 341: c5631. doi: 10.1136/bmj.c5631.
23. Parker C, Coupland C, Hippisley-Cox J,. Antipsychotic drugs and risk of venous thromboembolism: Nested case-control study. BMJ 2010; 341: c4245. doi: 10.1136/bmj.c4245.
24. Allenet B, Schmidlin S, Genty C, Bosson J,. Antipsychotic drugs and risk of pulmonary embolism. Pharmacoepidemiol. Drug Saf. 2012; 21: 42-48. doi: 10.1002/pds.2210.
25. Kamijo Y, Soma K, Nagai T, Kurihara K, Ohwada T,. Acute massive pulmonary thromboembolism associated with risperidone and conventional phenothiazines. Circ. J. 2003; 67: 46-48.
26. Borras L, Eytan A, de Timary P, Constant E, Huguelet P, Hermans C,. Pulmonary thromboembolism associated with olanzapine and risperidone. J. Emerg. Med. 2007; 35: 159-161.
27. del Conde I, Goldhaber S,. Pulmonary embolism possibly associated with olanzapine. Thromb. Haemost. 2006; 96: 690-691.
28. Hägg S, Tatting P, Spigset O,. Olanzapine and venous thromboembolism. Int. Clin. Psychopharmacol. 2003; 18: 299-300.
29. Kannan R, Molina D,. Olanzapine: A new risk factor for pulmonary embolus? Am. J. Forensic Med. Pathol. 2008; 29: 368-370.
30. Malý R, Masopust J, Hosák L, Urban A,. Four cases of venous thromboembolism associated with olanzapine. Psychiatry Clin. Neurosci. 2009; 63: 116-118.
31. Toki S, Morinobu S, Toshibo A, Yamawaki S,. A case of venous thromboembolism probably associated with hyperprolactinemia after the addition of olanzapine to typical antipsychotics. J. Clin. Psychiatry 2004; 65: 1576-1577.
32. Waage I, Gedde-Dahl A,. Pulmonary embolism possibly associated with olanzapine treatment. BMJ 2003; 327: 1384.
33. Zhang R, Dong L, Shao F, Tan X, Ying K,. Antipsychotics and venous thromboembolism risk: A meta-analysis. Pharmacopsychiatry 2011; 44: 183-188.
34. Knudsen J, Kortepeter C, Dubitsky G, Ahmad S, Chen M,. Antipsychotic drugs and venous thromboembolism (letter). Lancet 2000; 356: 252-253.
35. Kortepeter C, Chen M, Knudsen J, Dubitsky G, Ahmad S, Beitz J,. Clozapine and venous thromboembolism. Am. J. Psychiatry 2002; 159: 876-877.
36. Paciullo CHA,. Evaluating the association between clozapine and venous thromboembolism. Am. J. Health-Syst. Pharm. 2008; 65: 1825-1829.
37. Taylor D, Paton C, Kerwin R,. Prescribing Guidelines, 9th edn. Informa healthcare, London, 2007.
38. Axelsson S, Hägg S, Eriksson A, Lindahl T, Whiss P,. In vitro effects of antipsychotics of human platelet adhesion and aggregation and plasma coagulation. Clin. Exp. Pharmacol. Physiol. 2007; 34: 775-780.
39. Löffler S, Löffler-Ensgraber M, Fehsel K, Klimke A,. Clozapine therapy raises serum concentrations of high sensitive C-reactive protein in schizophrenic patients. Int. Clin. Psychopharmacol. 2010; 25: 101-106.
40. Tiihonen J, Lonnquist J, Wahlbeck K, et al. 11-year follow-up of mortality in patients with schizophrenia: A population-based cohort study (FIN11 study). Lancet 2009; 374: 620-627.
41. Stahl S, Mignon L, Meyer J,. Which comes first: Atypical antipsychotic treatment or cardiometabolic risk? Acta Psychiatr. Scand. 2009; 119: 171-179.
42. Hem E, Steen O, Opjordsmoen S,. Thrombosis associated with physical restraints. Acta Psychiatr. Scand. 2001; 103: 73-76.
43. Lazarus A,. Physical restraints, thromboembolism, and death in 2 patients. J. Clin. Psychiatry 2001; 63: 207-208.
44. Van Harten PM, Van Agtmael MA,. Complete anticoagulation for treatment of neuroleptic malignant syndrome? Am. J. Psychiatry 1995; 152: 1103-1104.
45. Strudsholm U, Johannessen L, Foldager L, Munk-Jørgensen P,. Increased risk for pulmonary embolism in patients with bipolar disorder. Bipolar Disord. 2005; 7: 77-81.
46. Hindersin P, Siegmund R, Körting H,. Thrombophile diathesen als Hämostasestörungen bei akuten psychosen. Psychiatr. Neurol. Med. Psychol. 1984; 36: 702-709.
47. Masopust J, Malý R, Andrýs C, Vališ M, Bažant J, Hosák L,. Markers of thrombogenesis are activated in unmedicated patients with acute psychosis: A matched case control study. BMC Psychiatry 2011; 11: 2.
48. Canoso R, Oliveira R, Nixon R,. Neuroleptic-associated autoantibodies-A prevalence study. Biol. Psychiatry 1990; 27: 863-870.
49. Schwartz M, Rochas M, Weller B, et al. High association of cardiolipin antibodies with psychosis. J. Clin. Psychiatry 1998; 59: 20-23.
50. Davis S, Kern H, Asokan R,. Antiphospholipid antibodies associated with clozapine treatment. Am. J. Hematol. 1994; 46: 166-167.
51. Firer M, Sirota P, Schild K, Elizur A, Slor H,. Anticardiolipin antibodies are elevated in drug-free, multiply affected families with schizophrenia. J. Clin. Immunol. 1994; 14: 73-78.
52. Chengappa K, Carpenter A, Keshavan M, et al. Elevated IgG and IgM anticardiolipin antibodies in a subgroup of medicated and unmedicated schizophrenic patients. Biol. Psychiatry 1991; 30: 731-735.
53. Shen H, Li R, Xiao H, Zhou Q, Cui Q, Chen J,. Higher serum clozapine level is associated with increased antiphospholipid antibodies in schizophrenia patients. J. Psychiatr. Res. 2008; 43: 615-619.
54. Schwartz M, Kormilachev M, Kushnir M, Keller B, Rochas M, Toubi E,. Lupus anticoagulant and anticardiolipin antibodies in serum of patients treated with risperidone. J. Clin. Psychiatry 2009; 70: 769-771.
55. Halacheva K, Dimova S, Tolev T, Dimov D, Nikolova M,. Elevated anticardiolipin antibodies in schizophrenic patients before and during neuroleptic medication. Psychiatry Res. 2009; 169: 51-55.
56. Jones A, Mowry B, Pender M, Greer J,. Immune dysreglation and self-reactivity in schizophrenia: Do some cases of schizophrenia have an autoimmune basis? Immunol. Cell Biol. 2005; 83: 9-17.
57. Leuci E, Manenti L, Maggini C,. Anti-phospholipid antibodies, neuroleptic treatment and cardiovascular morbidity. Br. J. Psychiatry 2007; 190: 81.
58. Boullin D, Orr M, Peters J,. The platelet as a model for investigating the clinical efficacy of centrally acting drugs: Relations between platelet aggregation and clinical condition in schizophrenics treated with chlorpromazine. In:, de Gaetano G, Garattini S, (eds). Platelets: A Multidisciplinary Approach. Raven Press, New York, 1978; 389-410.
59. Oruch R, Hodneland E, Pryme I, Holmsen H,. In thrombin stimulated human platelets Citalopram, Promethazine, Risperidone, and Ziprasidone, but not Diazepam, may exert their pharmacological effects also through intercalation in membrane phospholipids in a receptor-independent manner. J. Chem. Biol. 2009; 2: 89-103.
60. De Clerck F, Somers Y, Mannaert E, Greenspan A, Eerdekens M,. In vitro effects of risperidone and 9-hydroxyrisperidone on human platelet function, plasma coagulation, and fibrinolysis. Clin. Ther. 2004; 26: 1261-1273.
61. Dietrich-Muszalska A, Rabe-Jablonska J, Nowak P, Kontek B,. The first- and second-generation antipsychotic drugs affect ADP-induced platelet aggregation. World J. Biol. Psychiatry 2010; 11: 268-275.
62. Carrizo E, Fernández V, Quintero J, et al. Coagulation and inflammation markers during atypical or typical antipsychotic treatment in schizophrenia patients and drug-free first-degree relatives. Schizophr. Res. 2008; 103: 83-93.
63. Švestka J, Synek O, Tomanová J, Rodáková I, Cejpková A,. Differences in the effect of second-generation antipsychotics on prolactinaemia: Six weeks open-label trial in female in-patients. Neuroendocrinol. Lett. 2007; 28: 881-888.
64. Wallaschofski H, Donné M, Eigenthaler M, et al. PRL as a novel potent cofactor for platelet aggregation. J. Clin. Endocrinol. Metab. 2001; 86: 5912-5919.
65. Wallaschofski H, Eigenthaler M, Kiefer M, et al. Hyperprolactinemia in patients on antipsychotics drugs causes ADP-stimulated platelet activation that might explain the increased risk for venous thromboembolism: Pilot study. J. Clin. Psychofarmacol. 2003; 23: 479-483.
66. Dunn E, Grant P,. Atherothrombosis and the metabolic syndrome. In:, Byrne CHD, Wild SH, (eds). The Metabolic Syndrome. John Wiley & Sons, Ltd., London, 2005; 163-187.
67. Liperoti R,. Antipsychotics and the risk of velus thromboembolism. BMJ 2010; 341: 613-614.
68. Abdollahi M, Cuschman M, Rosendaal F,. Obesity: Risk factor of venous thrombosis and the interaction with coagulation factor levels an oral contraceptive use. Thromb. Haemost. 2003; 89: 493-498.
69. Phillips L, Prins J,. The link between abdominal obesity and the metabolic syndrome. Curr. Hypertens. Rep. 2008; 10: 156-164.
70. Applebaum J, Shimon H, Sela B, Belmaker R, Levine J,. Homocysteine levels in newly admitted schizophrenic patients. J. Psychiatr. Res. 2004; 38: 413-416.
71. Haidemenos A, Kontis D, Gazi A, Kallai E, Allin M, Lucia B,. Plasma homocysteine, folate and B12 in chronic schizophrenia. Prog. Neuropsychopharmacol Biol. Psychiatry 2007; 31: 1289-1296.
72. Henderson D, Copeland P, Nguyen D, et al. Homocysteine levels and glucose metabolism in non-obese, non-diabetic chronic schizophrenia. Acta Psychiatr. Scand. 2006; 113: 121-125.
73. Reif A, Schneider M, Kamolz S, Pfuhlmann B,. Homocysteinemia in psychiatric disorders: Association with dementia and depression, but not schizophrenia in female patients. J. Neural Transm. 2003; 110: 1401-1411.
74. Oger E, Lacut K, Le GG, et al. Interrelation of hyperhomocysteinemia and inherited risk factors for venous thromboembolism. Results from the EDITH study: A hospital-based case-control study. Thromb. Res. 2007; 120: 207-214.
75. Rosendaal F,. Risk factors for venous thrombotic disease. Thromb. Haemost. 1999; 82: 610-619.
76. Laursen S, Jensen T, Bolwig T, Olsen N,. Deep venous thrombosis and pulmonary embolism following physical restraint. Acta Psychiatr. Scand. 2005; 111: 324-327.
77. Malý R, Masopust J, Hosák L, Konupcíková K,. Assessment of a risk of venous thromboembolism and its possible prevention in psychiatric patients. Psychiatry Clin. Neurosci. 2008; 62: 3-8.
78. Masopust J, Konupcíková K, Malý R, Kalnická D, Bažant J, Hosák L,. Prospektivní sledování prevence tromboembolismu u imobilizovaných psychiatrických pacientu. Ces. a slov. Psychiat. 2010; 106: 577-583.
79. De Hert M, Einfinger G, Scherpenberg E, Wampers M, Peuskens J,. The prevention of deep venous thrombosis in physically restrained patients with schizophrenia. Int. J. Clin. Pract. 2010; 64: 1109-1115.